Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dosing in psoriatic arthritis
NCT00245960Phase 4Completed
- Sponsor
- Pfizer
- Start
- Dec 2005
- Primary completion
- Mar 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 26
01
Overview
Phase 4, randomised, double-blind trial of etanercept in psoriatic arthritis (PsA) and plaque psoriasis (2 arms), sponsored by Pfizer. Primary endpoint: Physician Global Assessment of Psoriasis at 12 weeks. Started Dec 2005; status: completed.
02
Drugs
etanercept
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on NCT00245960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00245960.